Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
12-14 August, 2025
Not Confirmed
Not Confirmed
17-21 August, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
12-14 August, 2025
Industry Trade Show
Not Confirmed
17-21 August, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
24 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250723072832/en/Galderma-Delivers-Record-First-Half-2025-Net-Sales-of-2.448-Billion-USD-and-12.2-Year-on-Year-Growth-at-Constant-Currency-Raises-Full-Year-Top-Line-Guidance
17 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250716698427/en/Galderma-Unveils-Final-Nine-Month-Data-Showing-Lasting-Efficacy-and-Patient-Satisfaction-With-Its-Injectable-Aesthetics-Portfolio-When-Addressing-Facial-Aesthetic-Changes-After-Medication-Driven-Weight-Loss
26 Jun 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761390
25 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250624095800/en/Galderma-Initiates-Two-New-Clinical-Trials-Investigating-Nemolizumab-in-Patients-With-Systemic-Sclerosis-and-Chronic-Pruritus-of-Unknown-Origin
18 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250617336479/en/ICD-2025-New-data-demonstrate-Nemluvios-nemolizumab-favorable-safety-profile-and-sustained-and-clinically-meaningful-improvements-in-symptoms-of-prurigo-nodularis-up-to-two-years
12 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250611351754/en/Galdermas-Nemluvio-nemolizumab-Receives-National-Institute-for-Health-and-Care-Excellence-NICE-Recommendation-for-Moderate-to-severe-Atopic-Dermatitis-in-England-and-Wales
ABOUT THIS PAGE